Newbridge Financial Services Group, Inc. Madrigal Pharmaceuticals, Inc. Call Options Transaction History
Newbridge Financial Services Group, Inc.
- $224 Million
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MDGL
# of Institutions
315Shares Held
20MCall Options Held
824KPut Options Held
1.04M-
Janus Henderson Group PLC London, X02.6MShares$707 Million0.39% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$535 Million6.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.94MShares$528 Million6.26% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.78MShares$482 Million34.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.67MShares$453 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.65B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...